Ken Griffin
GNTA

Ken Griffin’s Genenta Science GNTA Stock Holding History

Ken Griffin’s Portfolio GNTA Stock Details GNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-655,164
Closed -$976K – 13450
2025
Q4 		$976K Buy
655,164
+642,678
+5,147% +$1.51M ﹤0.01% 7441
2025
Q3 		$41K Buy
+12,486
New +$44.2K ﹤0.01% 12285
2025
Q1 		– Sell
-11,167
Closed -$46.5K – 14890
2024
Q4 		$46.5K Buy
+11,167
New +$57.1K ﹤0.01% 12465

Other funds holding GNTA

ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
AG
AlTi Global New York $4.84B AUM 25.68% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $2.96B AUM 25.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ken Griffin's GNTA Position: Q1 2026 in Review

Ken Griffin sold out of Genenta Science (GNTA) in Q1 2026, closing a stake of 655,164 shares — an estimated $976K sold.

Ken Griffin first reported a position in GNTA in Q4 2024 and held it in 3 quarters. The position peaked at $976K in Q4 2025. 11 funds tracked by Wall St. Rank hold GNTA as of Q1 2026.

  • Ken Griffin reported no remaining Genenta Science position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 655,164 Genenta Science shares in Q1 2026, an estimated $976K.
  • Ken Griffin first reported a position in Genenta Science in Q4 2024 and held it in 3 quarters.
  • Ken Griffin's Genenta Science position peaked at $976K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Genenta Science as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.